Trial Profile
Study on changes in urinary glucose concentrations in Type 2 diabetes patients treated with the selective SGLT2 inhibitor luseogliflozin
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Jan 2022
Price :
$35
*
At a glance
- Drugs Luseogliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 01 Dec 2021 Primary endpoint (Body weight) has been met, as per results published in the Diabetes Research and Clinical Practice.
- 01 Dec 2021 Primary endpoint (HbA1c) has been met, as per results published in the Diabetes Research and Clinical Practice.
- 01 Dec 2021 Primary endpoint (Fasting blood glucose level) has been met, as per results published in the Diabetes Research and Clinical Practice.